thank call. Good joining Thank the and afternoon, for all Jesse. you, you
anticipated have near-term half our and have greater were disappointed are in fiscal Let results year results faced quarterly the that that me here start we saying outlook. our and our by near-term impacted and of challenges second with than
making to goals of the our year CAGR Day, 'XX. XXXX fiscal confident to the Fiscal we XXXX markets into a we a remain EBITDA are business, and adjusted includes our revenue will few years. at oncology. out important company by fall grow end fastest-growing investing remains which substantial we as -- adjusted we of revenue and achieve that EBITDA doubling Investor the to laid which our growth some to an of on infrastructure believe radiation service track entrance X% our sustainable we and However, are that over the contribute X% year all introducing advanced in capabilities in for next
quarter did a The play factors. few not to due as out expected key
on have to had quarter, a meaningful systems ship impact top First, line and EBITDA. pushed adjusted had additional we both this which which QX, X our would expected to
is that it these becoming there have lower believe much we Additionally, in near is budgets And evident budget the longer in capital weakness in the a U.S., second reduced and of of which the a region substantial We slowdown to had equipment our but fiscal year, margin the largest in equipment highest saw we slow priority term. for cycles. half broader expected capital due is deployment to XXXX. demand contributed ramp one and the to markets, both capital radiotherapy equipment more in budgets
Finally, system planning market precision the the Tomo that for is regulatory equipment with while we to C. the await approval China, received to C have into treatment approval pleased used still Tono
quickest China optionality a we future. our could into the regulatory backlog. the take done owned system, to gives gain us submissions market the provide for the the Furthermore, submission discussed, treatment by system. precision precision the strategically the design system system, treatment previously to so was go-to-market within separate was S and from for As build strategy regulatory we a submission which the license greater Accuray planning for separate approval Tomo separated orders This allowing planning the order us
until we end approval, execute sites. user the shipments our report Tomo step full venture which ship cannot to our our we joint allows reminder, represents a receive launch, final customer margins This to market the at As this customers. C these installation coming the to up expect for full adjusted Despite communicated systems on addressable quarters, track and EBITDA to set these plan to the in X-year us market Investor Day. the FY will revenues 'XX retrieve which a above our the associated growth in with at and headwinds, on we overall return we including
underlying Going demand. believe timing this is a reflection a deeper not our mainly U.S. and business, we into issue of
end replacement for drive the We The base of strong installed support. and continue will parts are recommended expect age guidelines demand. the aged and many availability service have exceeded the potential to of of nearing for units
As longer continued installation in anticipated. we continuing take saw has QX, saw lines QX mentioned during this to time installation the cycles in the materialize we we conversion customer to backlog originally and and last in where longer earnings than U.S. call,
customers capital and revenue supports to surveyed in lesser in This Street slowdown surveyed capital validate hospital service observations. the administrators which greater a on product report understand extent, impacted in installation both priorities, the published activity. equipment Further, to leading our in Wall which depth, we March, and a U.S. analyst U.S. U.S. research this also our purchasing a To equipment
due improvement Some these include customers that capital resubmit to capital calendar expected allocated to budgets in XXXX, in lower of on required year higher for priority with spending the rated were XXXX. was radiotherapy costs. additional list for were gradual Many
the I capital expected quarter product results. can a perspective. 'XX to and Ali makes showcase equipment start the market in are one And performance, to our expected have will shift and at quarter capital a year share our impact from it is increase where fiscal look believe moving for that volume and revenue a to business, long-cycle is improve challenges, sizable radiotherapy Despite trailing company's to when reprioritized. quarter 'XX this to on longer-term through with given XX-month sense Finally, to we business, think deliver next are history gradual best the will recovery entering from both equipment on in fiscal we that a the budgets we these a fourth which basis We forward. year dynamic in our the
which and business. ultimately into orders revenue, is will innovations XX% a the a trailing market, order the in are growth customers is as impact are adopting margin the QX as of on and into which rate growing global than a we and share represent I future well and strong the strong quarter, adjusted am for indicators that signal leading the the X.X growth of to growth encouraged for both our very that of at expect XX-month basis which X% ratio product book-to-bill future. gain by EBITDA our positive translate faster
of performance growth base. Another is our global the installed metric key
that a strategy further with XX- a to Reflecting our addition of base and emerging company, performance, X-year service base, with the key of the grew to the pleased will fast-growing Accuray our base installed XX-year to focus period. X% installed year-over-year region expect into driven our is are largest our existing a revenue EIMEA basis. base X% grew over upgrading in very a period Our the the trailing strength and warranty which on for we I'm growth region, revenue markets, X% from patient strategic contract access. in following adding net customers part drive which regional which contract and service X% Installed drive on we growth means new up year-over-year XX-month is
XX% and on orders a trailing X% basis. grew XX-month in EIMEA revenue
on year and is the growth treatment X% system demand region to and gained and and revenue for We order to our the obtain in and regulatory APAC China growth XX% revenue for our largest key XX-month Once to pent-up obtain planning we drive we final expect unlock growth end precision market unleash with the team double-digit becoming C, our will year-over-year EIMEA deliver step in which fiscal basis. fiscal revenue deferred a Tomo the the we market second approval year-end, with traction. share order installation subregions. fast region and by margin expect trailing
unfavorable region, where XX% due The a total region offset orders impact offerings and a replacing realized down to be continues are Accuray Japan in XX% profitable are trailing from and taking X% the competitive XX-month region orders actions our negative was revenue additional we The is time. commercial on highly of of Japan help to FX, which FX. enhanced over for #X here, are pricing increased on expected primarily systems. to basis, to of the QX impact be but market share, we on including
and trailing basis. expect as the opening fiscal region for down than XX% trailing And I The on QX X% year-over-year, in in pace on but and XX-month Orders for up be down gradually were the down a to full region XX% comments, was the basis. a Finally, my quarter, mentioned but the performed year. slower recover, we a QX. U.S. XX-month we XX% QX down revenue in at Americas expected
other is our our commercial Our to improve as closer strategy flexible support. U.S. get players, where customers, our customers is this to in increased including expect even during for financing, time and satisfaction, the activities solutions, it from flexing user but our to challenging industry not partnerships instead enhanced U.S. field offering retreat increasing extremely engagement we
hospitals. committed radiotherapy continues Care the be is driver for to to profit tight Cancer while a being future. we top And partner forward, the and valued in remain now shifting and capital allocation
inauguration U.S. recent through facility obtain are highlights within of so centers we make China Other equipment clinical for with be our this well the for positioned orders around in hub the to Accuray easier will addition Switzerland. new world well will strategically to improved, building it innovation and capital of care on joint be focus other our new venture. to education. network when is company region. share accurate training teams medical locations include the conditions as These Genolier, and take the Japan the sites in of training as located Our key state-of-the-art partnership This located the backlog our most that the to center, important
centers in new training will investment these our in in expect global growth service training coming the contribute that We revenue to generate quarters. will
pillar Type CyberKnife for the and advancing Equipment the the B the both China meeting, in market Expo strategic Fair is In showcased our recently China We addition, furthering Shanghai, over held is largest participating. patient company. the the the C Medical equipment important countries, China at underpenetrated XXX,XXX C systems medical the access high-growth milestone with Tomo introduction in of of Tomo an full into
where the we first India, approval calendar awaiting our also continue for year-end market are the regulatory access early expected is for by We launch full launch, XXXX. product market which Helix, efforts in non-China
margin collaboration performance. in we predicting that a AI-driven in system also radiotherapy part aerospace to an announced Airbus, a strategy, we leader industry are develop entering expansion for Oncopole As today solution into agreement IUCT and with of our artificial intelligence, France
failure and level performance system component develop monitor us a We predict methodology, will collaborate issues. prediction to to address will allow to which proactively
costs operating reduced this will margins further that consumption. and a better expect patient and We into parts reducing strengthened translate service experience by
the new to ] this years as and is between the online Finally, recognize to partners progress plan professionals we the service of include and provide ESTRO their of head patients , Meeting. Annual that from end ability CyberComm, particularly at of week, Highlights adaptation solutions Radiation with ESTRO faster. of the designed time [ perform we treating enable to to occur of account industry radiation and physics commissioning in This to for application may the celebrate groundbreaking SX benefit may meaningful will CyberKnife to expand works patients Oncology's treatment intended ESTRO, changes who meeting European that with CNO and from will collaborating develop sessions. treatment significantly technologies offering health care reduce a access to begin customers to therapy year's Society customers systems a substantially care.
key on an product thought important Accuray Technology believe we our SBRT symposium the to with also an deliver. stereotactic -- the of Precision this demonstrating use innovation radiosurgery strategy ESTRO, is care pillar innovation, at is leaders led panel that will elite of driving drive positioned addition year's by to In well in we where advance and leadership clinical treatments opinion to
to fuel where strongest conditions. solutions. differentiated challenges and results, regions long-term the expect we current we continue I the as confident share the will In of of look and summary, disappointed to grow the we with understand QX see U.S. in the increase for we while our growing In value we signals remain term, near improvement strategy success our to in our are
discuss it continued the and pipeline, in clearances new We focus financials. innovation our and near-term we to have the Ali the meaningful growth balance and will for product drivers will our strength service both margin growth hand expected sheet to expansion of investment improving solutions, regulatory and now in believe over position well increasing us I on profitability. and substantial services,
